.png)
.png)
RNID shine a spotlight on the hearing therapeutics landscape
In this blog, Melissa Hayman, Hearing Therapeutics Manager at RNID, BIA’s charity partner of the year introduces a blog series to be published over the coming months which will examine the hearing therapeutics landscape.
Continuity and change: Labour’s life science strategy
Herbie Lambden, Senior Policy and Public Affairs Executive at the BIA, provides a rundown of the BIA Committee Summit, which took place in Westminster on 21 February.
CEO Update - 22 April 2024
The UK's engineering biology scene was out in force at a Number 10 Downing Street reception last week. It was great to celebrate the developments in our community network together with ministers and investors.
Step up and create more inclusive workplaces within the biotech sector
In last year’s Diversity and Inclusion in UK Biotech survey conducted by the BIA, hearing loss emerged as one of the most prevalent disabilities. With Deaf Awareness Week 2024 (6-12 May) fast approaching, the BIA has teamed up with its charity partner, RNID, to offer valuable resources and initiatives for creating more inclusive workplaces across the biotech sector.
Investing in life science – learnings from the first round of investments from Discovery Park Ventures
Launched in May 2022 by thriving life science community Discovery Park, Discovery Park Ventures (DPV) is an investment fund that invests in ambitious and growing life sciences companies, driving disruptive innovation and catalysing economic growth. Initially a £1 million fund, DPV has now expanded to £3 million.
AI in life sciences: future-proofing strategies
In the final piece of the 'AI in life sciences' series, Jenny Yu, Marsh’s Life Sciences industry practice leader and experts from law firm Kennedys emphasize essential steps for life sciences companies to develop and implement a successful AI business strategy. They delve into effective management of outcomes from AI technologies and strategies to mitigate potential risks.
CEO Update - 15 April 2024
In case you missed it last week, post-Brexit border paperwork and inspections have been postponed for the life sciences sector, thanks to BIA work. Importers of laboratory reagents and materials used in the manufacture of medicines in the UK’s life sciences sector have been given a six-month extension to make the necessary changes to their supply chains for new post-Brexit border paperwork and border inspections.
CEO Update - 8 April 2024
I don’t always start Newscast with a technical detail – but this one matters and underpins the work of many, many companies in our Association. In short, keep doing your experiments and manufacturing medicines as normal as we work hard to keep your reagents and materials supply chain operating smoothly.
How to build a high-performance life science team
In this blog, Olivia Fletcher-Hogg, Programme Manager at Pioneer Group, provides actionable insights for building high-performance teams in the life sciences and biotech sector, from fostering a positive work culture to empowering employee development.
AI in life sciences: regulating AI technologies and the product liability implications
Recent regulatory developments in the EU and UK suggest a proactive stance on governing AI technologies, with the EU introducing comprehensive regulations and the UK proposing reforms to align with emerging digital technologies.
CEO Update - 25 March 2024
I’m delighted to be opening PULSE this morning. It is a free three-day leadership and entrepreneurship training programme for up-and-coming life sciences entrepreneurs that we’ve developed and delivered with the Francis Crick Institute. Read on for the latest on EU biotech initiatives, Biosecurity Leadership Council and boost for UK cell and gene therapy.
AI in life sciences: an evolving risk landscape
In this article, Marsh’s Life Sciences industry practice leader Jenny Yu and experts from Kennedys take a look at the topic of AI in the life sciences sector, the associated risks regulation and potential liability issues, as well as how companies can seek to ‘future-proof’ themselves in the face of rapid change.
CEO Update - 18 March 2024
A year ago, the life sciences sector faced a significant challenge with the SVB UK collapse. This event threatened to disrupt vital research and development for many companies. Today, we're taking a moment to reflect on that experience and share valuable resources to help us all build a more resilient future.
Member spotlight: Meet OMass Therapeutics
In this blog, Ros Deegan, CEO of OMass Therapeutics, a member of the BIA Board and a member of the Prime Ministers 2024 Business Council, shares how the company is pioneering new approaches to drug discovery, targeting challenging diseases with their advanced platform.
CEO Update - 11 March 2024
The Chancellor's Budget last week had plenty for UK life sciences. The BIA’s mission to unlock pension funds for investment into UK life sciences took a great leap forward with the announcement that the life sciences team of Intermediate Capital Group (ICG) has successfully partnered with Phoenix Group.
Breaking Barriers: Leigh Stoddart reflects on #IWD2024
Dr. Leigh Stoddart, Principal Scientist at Excellerate Bioscience and newly announced Fellow for the British Pharmacological Society (BPS), reflects on her career journey on International Women’s Day 2024. From her undergrad days at Unilever to her current role, Leigh's passion for receptor pharmacology shines. She discusses her role at Excellerate, the significance of her BPS fellowship, and the importance of International Women's Day in science.
IRC unveils comprehensive analysis of the UK's deep biotech infrastructure landscape
In this blog, Maddie Cass, Senior Policy and Public Affairs Executive at the BIA, shares insights on the Innovation & Research Caucus (IRC) recent report, which examines the current state of the UK's non-health engineering biology infrastructure.
Spring Budget 2024 life sciences announcements
In this blog, Dr Martin Turner, Associate Director, Policy, Public Affairs & Investor Relations at BIA takes a closer look at the impact of the Spring Budget on UK life sciences, examines key announcements and invites you to join our webinar tomorrow for a deeper dive into the implications.
CEO Update - 4 March 2024
It is the Budget week at Westminster and all eyes will be on the Chancellor's statement this Wednesday. We've already seen Jeremy Hunt doubled down on the pensions reform agenda in weekend reporting and I'm hopeful we'll see more to support the life science sector this week.
Reflections on the BIA Committee Summit 2024
Herbie Lambden, Senior Policy and Public Affairs Executive at the BIA, provides a rundown of the BIA Committee Summit, which took place in Westminster on 21 February.